Stereotactic Body Radiotherapy (SBRT) of Previously Unirradiated Mucosal Head and Neck Squamous Cell Carcinoma (SCC) - Takeaways - MDSpire

Stereotactic Body Radiotherapy for Untreated Mucosal Squamous Cell Carcinoma of the Head and Neck

  • By

  • Mohammed Aldohan

  • Irene Karam

  • Amir H. Safavi

  • Lee Chin

  • Liying Zhang

  • Ethan Gooanratne

  • Madette Galapin

  • Antoine Eskander

  • Kevin Higgins

  • Danny Enepekides

  • Ian Poon

  • June 29, 2026

Share

  • 1

    Stereotactic body radiotherapy (SBRT) was evaluated for 74 patients with untreated mucosal squamous cell carcinoma of the head and neck.

  • 2

    Patients selected for SBRT were deemed unsuitable for radical treatment and systemic therapy, highlighting a need for alternative options.

  • 3

    SBRT dosages ranged from 35 to 50 Gy delivered in 5 fractions, aiming for high tumor coverage with minimal toxicity.

  • 4

    Outcomes measured included local failure, regional recurrence, overall survival, and progression-free survival using Kaplan-Meier plots.

  • 5

    Toxicity was assessed according to the Common Terminology Criteria for Adverse Events, version 5.0.

Original Source(s)

Stereotactic Body Radiotherapy (SBRT) of Previously Unirradiated Mucosal Head and Neck Squamous Cell Carcinoma (SCC)

  • by Mohammed Aldohan, Irene Karam, Amir H. Safavi, Lee Chin, Liying Zhang, Ethan Gooanratne, Madette Galapin, Antoine Eskander, Kevin Higgins, Danny Enepekides, Ian Poon

  • June 29, 2026

Related Content

Circadian rhythms in the tumor microenvironment: spatiotemporal immune regulation and chronotherapeutic opportunities

Lipid metabolic plasticity in glioblastoma: mechanisms, tumor microenvironment remodeling, and therapeutic opportunities

Treatment patterns and outcomes of patients with a diagnosis of metastatic pancreatic adenocarcinoma in the United States, 2019–2024